Health Care & Life Sciences » Biotechnology | Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. | Ownership

Companies that own Inovio Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BlackRock Fund Advisors
6,385,705
6.98%
281,901
0%
06/30/2018
SSgA Funds Management, Inc.
3,920,321
4.29%
-550,651
0%
06/30/2018
The Vanguard Group, Inc.
3,884,544
4.25%
127,750
0%
06/30/2018
Wasatch Advisors, Inc.
2,738,190
2.99%
174,911
0.09%
06/30/2018
ARK Investment Management LLC
1,194,657
1.31%
530,247
0.21%
06/30/2018
Northern Trust Investments, Inc.
1,032,447
1.12%
39,205
0%
06/30/2018
Geode Capital Management LLC
851,738
0.93%
46,437
0%
06/30/2018
Security Investors LLC
504,426
0.55%
-283
0.04%
06/30/2018
Citadel Advisors LLC
465,619
0.51%
14,609
0%
06/30/2018
Charles Schwab Investment Management, Inc.
445,846
0.49%
33,567
0%
06/30/2018

About Inovio Pharmaceuticals

View Profile
Address
660 West Germantown Pike
Plymouth Meeting Pennsylvania 19462
United States
Employees -
Website http://www.inovio.com
Updated 07/08/2019
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.